EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, And Market Forecast-2030.
M2 PRESSWIRE-August 24, 2021-: EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, And Market Forecast-2030
(C)1994-2021 M2 COMMUNICATIONS
RDATE:23082021
DelveInsight's 'EGFR Inhibitors-Induced Skin Disorders Market' report deliver an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
EGFR Inhibitors Induced Skin Disorders Market
The EGFR Inhibitors-Induced Skin Disorders market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM EGFR Inhibitors-Induced Skin Disorders market size from 2021 to 2030. The Report also covers current EGFR Inhibitors-Induced Skin Disorders treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
EGFR Inhibitors-Induced Skin Disorders Market Outlook
Inhibitors of the epidermal growth factor receptor (EGFR) are used in a growing range of tumor types to improve clinical outcomes. EGFR may be inhibited with anti-EGFR-specific monoclonal antibodies or small-molecule tyrosine kinase inhibitors. Dermatologic toxic effects are the most common side-effects associated with anti-EGFR therapy.
The treatment of EGFR inhibitor-related skin reactions is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR induced skin diseases in the US, EU, and Japan. The off-label therapeutic options used for anti-EGFR induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.
In contrast to acne vulgaris, topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions. Cream or lotion preparations are preferred to take advantage of an additional moisturization effect. Fissures are treated topically with propylene glycol 50%. For grade 3 rash, oral corticosteroids (methylprednisolone dose pack or prednisone 0.5 mg/kg for 7 days) are also considered to be beneficial.
The market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders. The treatment is mainly based on off-label therapies with limited safety and efficacy data. Corticosteroid use is also often limited due to their toxicity on long-term use. The patient population of cancers and EGFR inhibitor utilization is expected to increase throughout the forecast period (2021-2030). These may contribute to the rise of the patient population of EGFR...
To continue reading
Request your trial